The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...

AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published ...

The primary outcome was mean MDS-UPDRS part III OFF-medication scores at 96 weeks for exenatide versus placebo. This outcome was not met as no statistically significant difference was observed between ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s disease, finds a new study led by UCL Queen Square Institute of Neurology ...

Exenatide (Byetta) is a GLP-1-receptor agonist that recently was FDA-approved for treating type 2 diabetes. In an industry-sponsored randomized trial, 336 patients with suboptimally controlled ...

The arrival of the MG Cyberster marks a significant moment in the story of the Chinese-owned brand. With the old Morris Garages MG having a rich history of sports cars, any flagship performance ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Moana's island home of ...